Alex Philippidis is a Senior Business Editor at Inside Precision Medicine. He covers a diverse range of topics within medicine and healthcare, including healthcare technology, finance, and the evolving fields of cannabis and psychedelics. His work has been featured in notable publications such as Inside Precision Medicine and Genetic Engineering & Biotechnology News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Alex Philippidis mainly covers healthcare and pharmaceutical industry, focusing on investment analysis, private sector announcements, and press releases. He would likely be interested in receiving pitches related to breakthroughs in drug development, acquisitions within the biopharmaceutical industry, advancements in gene therapy as well as the application of AI in healthcare.
Given his interest in citing data and investment analysis, he might appreciate pitches that provide substantial data-driven insights into trends or companies within the healthcare and pharmaceutical sectors. Additionally, pitches featuring exclusive access to company executives for interviews or providing unique perspectives on M&A activities could also resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Alex Philippidis
Insilico Medicine (Hong Kong Exchange: 3696) , an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first half of 2026, driven by its series of partnerships and a wide-ranging pipeline whose first program has reached late-stage development this past week.
By: Alex Philippidis
AstraZeneca has acquired exclusive global rights to develop and commercialize Dizal Pharmaceutical's marketed lung cancer drug Zegfrovy® (sunvozertinib), through an agreement that could generate up to $1.5 billion for the spinout of the pharma giant's onetime Chinese R&D operation.
By: Fay Lin, Alex Philippidis, Uduak Thomas, Corinna Singleman
Credit: Yuichiro Chino / Moment / Getty Images
By: Alex Philippidis
The pharma giant's eighth acquisition announced this year would expand its neuroscience presence with pipeline led by Phase III treatment-resistant depression candidate
By: Alex Philippidis
10x Genomics says it is on track to build out a CLIA-certified laboratory set to open next year, part of the spatial and single-cell tools developer's expansion into clinical diagnostics launched earlier this year.
By: Alex Philippidis
Argenx has agreed to acquire Forte Biosciences for $2.2 billion, the companies said, in a deal intended to expand the buyer's immunology portfolio with an early clinical stage candidate that has shown promising data.
By: Alex Philippidis
Researchers from Latigo Biotherapeutics and its clinical partners have reported positive Phase IIb data for its lead pipeline candidate, the non-opioid acute pain treatment LTG-001, which showed significantly greater pain reduction scores than placebo over 48 hours in patients with moderate or severe pain after abdominoplasty.
By: Corinna Singleman, Alex Philippidis, Uduak Thomas
Credit: monsitj / Getty Images/iStockphoto In the business news section of this week's episode, Axiom Biosciences recently announced its
By: Alex Philippidis
Shares crater 80% after advisory committee sides with agency reviewers in recommending against approval of DMD cardiomyopathy cell therapy candidate, as August 22 PDUFA decision date looms
By: Alex Philippidis
The 4.5 year, up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked
